Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. . PLoS One 2022;17:e0276650.

Read + Share

Amedeo Smart

Independent Medical Education